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Bacterial foodborne pathogens are a significant health burden and the recent emergence
of pathogenic resistant strains due to the excessive use of antibiotics makes it more
difficult to effectively treat infections as a result of contaminated food. Awareness of this
impending health crisis has spurred the search for alternative antimicrobials with natural
plant antimicrobials being among the more promising candidates as these substances
have good acceptability and likely low toxicity levels as they have long been used
in traditional medicines. Resveratrol (3,5,4′-trihydroxystilbene) is a naturally occurring
stilbenoid which has been gaining considerable attention in medical field due to its
diverse biological activities - it has been reported to exhibit antioxidant, cardioprotective,
anti-diabetic, anticancer, and antiaging properties. Given that resveratrol is phytoalexin,
with increased synthesis in response to infection by phytopathogens, there has been
interest in exploring its antimicrobial activity. This review aims to provide an overview of the
published data on the antibacterial activity of resveratrol against foodborne pathogens, its
mechanisms of action as well as its possible applications in food packing and processing;
in addition we also summarize the current data on its potential synergism with known
antibacterials and future research and applications.
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INTRODUCTION
Foodborne illnesses resulting from of ingestion of food or drinks contaminated with pathogenic
microorganisms represent a global health concern (Lv et al., 2011). Transmission of foodborne
pathogens from contaminated food is a common health concern, the causative agents from bacteria,
viruses, parasites, chemicals and prions. Kirk et al. (2015) estimated there were 2 billion cases of
foodborne diseases in 2010 alone and over 1 million deaths with 78.7 million Disability Adjusted
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Life Years (DALYs) reported. About 582 million foodborne
diseases cases were due to transmission from contaminated
food, and the leading causative agent of foodborne illness
was Norovirus which caused 125 million cases whereas
Campylobacter spp. caused 96 million illness. The highest burden
was diarrhea due to infection by non-typhoidal Salmonella
enterica (NTS) which resulted in 4.07 million DALYs (Kirk et al.,
2015).
The continuous use of antimicrobial agents like antibiotics
is one of the main reasons antibiotic resistant bacteria strains
have developed. Overuse of antibiotics in agriculture where
they are used not only for treatment of infections but also for
promoting animal growth is a significant public health risk as
it promotes the of emergence and spread of antibiotic resistant
bacteria from food producing animals (Tan et al., 2014). For
example, the use of beta-lactams and ciprofloxacin resulted in
the emergence of resistant strains of Campylobacter spp. and the
use of streptomycin, sulfisoxazole and tetracycline resulted in
development of resistance in Escherichia coli (Das et al., 2017).
Since the introduction of tetracycline in 1957, the proportion
of tetracycline resistant E. coli isolated from poultry increased
from 3.5 to 63.2% in United Kingdom from 1957 to 1961 (Tellez
et al., 2013). In short, the rise in antibiotic resistance has led to
a decrease in the effectiveness of many antibiotics—a scenario
which has tremendous implications for the pharmaceutical,
medical, and food industries.
Given the significant morbidity and mortality associated with
foodborne pathogens, the pharmaceutical industry is investing
heavily in research looking for new inhibitory compounds from
natural sources that can be developed into new anti-microbial
drugs. Plant based medications have deep roots in medicinal lore,
with mankind having relied on natural products derived from
plants, animals, and microbes as remedies to treat illnesses for
a very long time (Tan et al., 2015, 2017; Tang et al., 2016; Chan
et al., 2017; Ser et al., 2017). In fact, in current clinical medicine,
many modern drugs actually originated from plants which are
rich in chemically diverse compounds and scaffolds (Fabricant
and Farnsworth, 2001; Ser et al., 2016; Yong et al., 2017). In
recent years, there has been increased interest in research seeking
plant derived antimicrobials as an alternative to antibiotics. In
addition to their efficacy in terms of antimicrobial properties,
a significant advantage of these substances is that bacteria are
less likely to develop resistance against them as they are acting
on more than one target in cells (Burt, 2004). Also, certain
plant derived antimicrobials are labeled as Generally Recognized
as Safe (GRAS), giving them a “greener” image that is more
acceptable to consumers (Xi et al., 2011). All these factors in
combination suggest that natural antimicrobials have significant
healthcare and market value given they match the increase
in demand of greener additives by the consumers, supporting
the value of research of plant based antimicrobials as potential
biopharmaceutical products (Lai et al., 2017).
Among the various groups of plant based natural products,
resveratrol (3,5,4′-trihydroxystilbene) seems highly promising
for its therapeutic applications. It is a compound present
in grape skins and wine, and is known to exhibit multi-
spectrum therapeutic applications having been reported
to exhibit anticancer, antiangiogenic, immunomodulatory,
cardioprotective, and antioxidant activity. Although there is still
very limited work on the antibacterial activity of resveratrol, it
has been shown that resveratrol exhibits antibacterial activity
against several Gram-positive and Gram-negative foodborne
bacteria (Chan, 2002; Tegos et al., 2002; Paulo et al., 2010;
Paolillo et al., 2011; Alvarez et al., 2012, 2013; Kumar et al.,
2012b; Plumed-Ferrer et al., 2013; Augustine et al., 2014;
Ferreira et al., 2014; Moran et al., 2014; Promgool et al., 2014;
Subramanian et al., 2014; Duarte et al., 2015; Kim et al., 2015;
Makwana et al., 2015; Ferreira and Domingues, 2016; Liu et al.,
2016; Seukep et al., 2016; Silva et al., 2016; Surendran Nair et al.,
2016; Klancnik et al., 2017; Lai et al., 2017; Lee and Lee, 2017;
Oliveira et al., 2017). This review aims to provide an overview
of the published data on the antibacterial activity of resveratrol
against foodborne pathogens, its mechanisms of action as well
as its possible applications in food packing and processing; in
addition we also summarize the current data on its potential
synergism with known antibacterials and future research and
applications. Figure 1 depicts the overview of this review.
OVERVIEW AND RATIONALE OF
RESVERATROL AS ANTIMICROBIAL
AGENT
Resveratrol is a naturally occurring phytoalexin belonging to the
stilbene family of phenolic compounds; it exists in either trans
or cis geometrical isomers with the trans isomer (Figure 2) being
the predominant isomer in plants (Filip et al., 2003; Catalgol
et al., 2012) and hence forming the focus of this review. First
isolated by Takaoka in 1940 from the roots of white hellebore
(Veratrum grandiflorumO. Loes), the compound was later named
resveratrol since it is a resorcinol derivative from Veratrum
species (Catalgol et al., 2012). As a polyphenolic compound,
resveratrol has been reported in over 100 medical and edible
plants such as Polygonum cuspidatum, Arachis hypogaea, Yucca
Shidigera, Cassia quinquangulata, Rheum rhamponticum, and
many more (Rocha-Gonzalez et al., 2008; Chachay et al., 2011).
In 1992, resveratrol, as the active component in red wine,
was believed to be responsible for the phenomenon known
as the “French paradox” whereby epidemiological data shows
that the French population have a lower mortality rate from
cardiovascular diseases (CHD) despite a relatively high dietary fat
consumption (Catalgol et al., 2012; Tome-Carneiro et al., 2013).
Renaud and de Lorgeril (1992) proposed that the lower mortality
rate of the French population—in spite of their relatively fatty
diet—from CHD was due to the moderate consumption of
resveratrol-containing wine, and suggested that the consumption
of wine inhibited platelet aggregation thus leading to reduced
risk of CHD (Renaud and de Lorgeril, 1992). In the following
years, resveratrol was very much in the spotlight with the first
evidence published of it potential to prevent carcinogenesis in
mice (Jang et al., 1997). Since then, resveratrol has received
considerable attention for its health promoting properties such
as its antioxidant, cardioprotective, anti-diabetic, anticancer, and
antiaging properties (Jung et al., 2009; Fernández-Mar et al.,
2012).
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FIGURE 1 | The overview of resveratrol as antibacterial agent against foodborne pathogens. (A) Resveratrol is found abundantly in the skin and leaves of grapevine
(Vitis vinifera). (B) Resveratrol has been shown to exhibit promising antibacterial properties against variety of foodborne pathogens such as E. coli, Listeria sp.,
Staphylococcus aureus, Campylobacter sp. and Vibrio sp. (C) Resveratrol was shown to inhibit electron transport chain (ETC) and F0F1-ATPase, leading to reduced
cellular energy production and thus proliferation of the microorganisms. (D) Resveratrol binds to Cu(II) to form a Cu(II)-peroxide complex, which binds DNA to form
DNA-resveratrol-Cu(II) ternary complex, leading to DNA scission and breakage. (E) Resveratrol inhibits cell division by downregulating FtsZ gene which responsible for
the formation of Z-ring required for prokaryotic cell division. (F) Resveratrol was demonstrated to be an effective antibiofilm and antiquorum sensing agent that
prevents biofilm formation as well as disrupts the pre-formed biofilm. Overall, resveratrol could be developed into biopharmaceutical product as well as food
preservatives in food industry to cope with food spoilage and foodborne outbreaks.
FIGURE 2 | Chemical structures of (A) trans-resveratrol and (B) cis-resveratrol.
Phytoalexins are naturally-occurring, low molecular weight
secondary metabolites produced by plants in respond to adverse
conditions such as biotic stress from bacteria, fungi, viruses,
and abiotic stress from chemical treatment (Filip et al., 2003;
Pangeni et al., 2014). For instance, resveratrol is known as a
major stilbene phytoalexin which is produced as an active defense
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mechanism to protect grape plants from phytopathogens. During
Botrytis cinerea fungal infection, the amount of resveratrol was
found to increase in the skin of infected grapes (Jeandet et al.,
1995). Moreover, the synthesis of resveratrol was also increased
in grapevine berries during fungal infection by Aspergillus
carbonarius (Bavaresco et al., 2008). Similarly, the bacterium
belonging to genus Bacillus was also shown to stimulate the
production of resveratrol in the leaves of grapevine plants (Paul
et al., 1998). Besides that, the grapevine Vitis vinifera which is
rich in resveratrol has also been used as popular folk remedy
to treat diarrhea, hemorrhage, varicose veins, inflammatory
disorder and also heal wounds and drain furuncles (Bombardelli
and Morazzoni, 1995; Pari and Suresh, 2008; Orhan et al.,
2009). Resveratrol, as a logical target, has been investigated in
the same manner as other plant derived phenolic compounds
(Chan et al., 2016), in many previous studies as alternatives to
antibiotics (Burt, 2004). The work so far appears encouraging
with resveratrol having been reported to exhibit antimicrobial
properties against bacteria (Hwang and Lim, 2015), yeasts (Jung
et al., 2007) and fungi (Jung et al., 2005).
IN VITRO ANTIBACTERIAL TESTS OF
RESVERATROL
Several analytical methods have been employed to evaluate
the antibacterial activity of resveratrol against foodborne
bacterial pathogens; with the two most important methods
used being the disk diffusion assay and broth microdilution
assay which enable an estimate of the efficacy of resveratrol
against a tested pathogen. Furthermore, several other advanced
techniques have also been adopted to evaluate the antibacterial
activity of resveratrol such as time kill analysis, scanning
electron microscopy, crystal violet biofilm assay, and quorum
sensing inhibition assay (Burt, 2004; O’toole, 2011). Based
on the available literature, resveratrol was demonstrated to
exhibit differential antibacterial activities against different
strains of foodborne pathogens including Staphylococcus aureus,
Bacillus cereus, Bacillus subtilis, and Listeria monocytogenes,
E. coli O157:H7, Salmonella Typhimurium, Vibrio cholera,
Campylobacter jejuni, Campylobacter coli, Arcobacter butzleri,
and Arcobacter cryaerophilus (Tables 1, 2).
According to the data from previous studies, the minimum
inhibitory concentration (MIC) of resveratrol against Gram-
negative ranged from 0.625–521µg/mL while the MIC of
resveratrol against Gram-positive bacteria ranged from 16.5–
260µg/mL. In general, previous studies indicated that resveratrol
exhibits better activity against Gram-positive bacteria than
Gram-negative bacteria. Using a simple analysis based on the data
collected, it was found that the mean MIC of resveratrol against
Gram-positive bacteria was 141.83 ± 18.30µg/ml while against
Gram-negative bacteria was 224.82 ± 39.41µg/ml. For instance,
Paulo et al. (2010) reported that the MIC of resveratrol toward
all tested Gram-negative bacteria were more than 400µg/mL
while MIC toward Gram-positive bacteria ranged from 50 to
100µg/mL. They proposed that the difference in susceptibilities
toward resveratrol might be attributed to the presence of a
hydrophilic outer membrane in Gram-negative bacteria which
is absent in Gram-positive bacteria. The hydrophilic outer
membrane may act as a protective layer resisting the diffusion
of hydrophobic molecules like resveratrol from penetrating the
bacterial cell, thereby reducing the efficacy of the antibacterial
action of resveratrol (Paulo et al., 2010). Besides that, the presence
of degradative and detoxifying enzymes in the periplasmic
space of Gram-negative bacteria could be another contributing
factor to reduced activity of resveratrol due to breakdown
of the resveratrol molecule by these enzymes (Beveridge,
1999). Another possibility of the observed lower sensitivity
demonstrated by Gram-negative bacteria toward resveratrol
could be the presence of multidrug resistance pumps (MDRPs)
on their cell surface which may be able to extrude resveratrol
from the cell. This appears to be unique to Gram negative rather
than Gram positive organisms as demonstrated by Tegos et al.
(2002) who reported that the MIC of resveratrol for S. aureus and
E. coli was 125µg/mL and 500µg/ml respectively. However, the
MIC of resveratrol for E. coli decreased by 16-fold in the presence
of aMDRPs inhibitor while for S. aureus, theMIC only decreased
by 2-fold which suggested the effect of MDRPs in reducing the
activity of resveratrol in Gram-negative bacteria (Tegos et al.,
2002). Nevertheless, it is still difficult to draw any definite
conclusions about the difference in susceptibility between Gram-
positive and Gram-negative bacteria toward resveratrol. A study
by Taguri et al. (2006) demonstrated that the susceptibility to
phenolic compounds was dependent on the bacterial species with
Gram-staining not necessarily correlating with the antimicrobial
efficacy.
Combinatorial therapy may be one strategy to address the
differential susceptibility toward resveratrol and development
of resistance, as it could potentially enhance the efficacy of
antimicrobials as well as to prevent emergence of resistant strains
by exploiting the synergism between multiple antimicrobials.
Kumar et al. (2012a) reported the existence of synergistic activity
of resveratrol and antibiotics, showing improved antibacterial
activity compared to treatment of resveratrol or the antibiotic
alone. The study revealed the synergism between resveratrol
and ciprofloxacin while additive effect between resveratrol
and cefotaxime against both Gram-negative or Gram-positive
bacteria (Kumar et al., 2012a). It may be pertinent for future
research to investigate the interactions between resveratrol with
other commonly used antibiotics in clinical medicine in order to
fully exploit resveratrol as a novel antibacterial agent.
POSSIBLE MODE OF ACTIONS OF
RESVERATROL AGAINST FOODBORNE
BACTERIA
Understanding the mechanisms underlying the actions of a
potential antibacterial molecule is key to assisting in identifying
the likely targets and predicting the possible outcomes of
resistance mechanisms that target bacteria may develop toward
the molecule. The exact mechanism of the antibacterial activities
of resveratrol against bacterial pathogens are still elusive.
Nevertheless, several studies have reported possible antibacterial
Frontiers in Pharmacology | www.frontiersin.org 4 February 2018 | Volume 9 | Article 102
Ma et al. Potential Resveratrol Use against Foodborne Pathogens
TABLE 1 | MIC of resveratrol against Gram-negative bacteria.
Gram types Bacterial pathogens Bacteria strains Source of bacterial strain MIC MBC References
Gram-negative Escherichia coli BW25113 derivative of E. coli K-12 W1485 400µg/mL – Liu et al., 2016
BCRC10675 Isolated from urine 521µg/mL – Lai et al., 2017
ATCC 25922 clinical isolate > 400µg/mL – Paulo et al., 2010
TISTR 780 Isolated from feces 128µg/mL – Promgool et al., 2014
ATCC 8739 Isolated from feces 64µg/mL 64µg/mL Seukep et al., 2016
AG100ATet – 128µg/mL 256µg/mL Seukep et al., 2016
AG102 – 32µg/mL 32µg/mL Seukep et al., 2016
MTCC 2622 Isolated from
stools of diphtheria convalescent
patients
32µg/mL 64µg/mL Kumar et al., 2012b
K-12 – 500µg/mL – Tegos et al., 2002
Escherichia coli O157:H7 BCRC 15374 Isolated from human feces 521µg/mL – Lai et al., 2017
Salmonella typhimurium ATCC 13311 Isolation from human feces (food
poisoning)
> 400µg/mL – Paulo et al., 2010
Unidentified – 5µg/mL – Lee and Lee, 2017
TISTR 292 Isolated from feces of man with food
poisoning
128µg/mL – Promgool et al., 2014
ST329 – 500µg/mL – Tegos et al., 2002
Vibrio cholera O1 MCVO9 Clinical isolate from cholera outbreak 60µg/mL – Augustine et al., 2014
ATCC 39315 Isolated from feces of cholera patient 0.625µg/mL – Kim et al., 2015
Campylobacter coli 873 Isolate from feces of patient with
acute gastroenteritis
50µg/mL – Duarte et al., 2015
Campylobacter jejuni 225421 Isolated from fresh poultry meat 100µg/mL – Duarte et al., 2015
K49/4 Isolated from food 313µg/mL – Klancnik et al., 2017
NCTC 11168 Isolated from human feces (reference
strain)
313µg/mL – Klancnik et al., 2017
Arcobacter butzleri AB36/11 Isolated from poultry caecum 100µg/mL – Duarte et al., 2015
INSA 776 Isolated from feces of patient with
diarrhea and abdominal pain
100µg/mL – Duarte et al., 2015
LMG 10828 Isolated from feces from man with
diarrhea
100µg/mL – Ferreira et al., 2014
Arcobacter cryaerophilus LMG 10829 Isolated from human blood 500µg/mL – Ferreira et al., 2014
TABLE 2 | MIC of resveratrol against Gram-positive bacteria.
Gram
types
Bacterial pathogens Bacteria strains Source of bacterial strain MIC MBC References
Gram-
positive
Staphylococcus aureus RN450 – 150µg/mL – Liu et al., 2016
ATCC 25923 Clinical isolate 100µg/mL – Paulo et al., 2010
ATCC 25923 Clinical isolate 200µg/mL > 400µg/mL Oliveira et al., 2017
MTCC 902 Isolated from man with septic arthritis 32µg/mL 32µg/mL Kumar et al., 2012b
8325-4 – 125µg/mL – Tegos et al., 2002
BCRC12655 Isolated from sliced turkey 130–260µg/mL Lai et al., 2017
BCRC10780 Isolated from human pleural fluid 130–260µg/mL – Lai et al., 2017
MRSA COL Clinical isolate 350µg/mL > 800µg/mL Qin et al., 2014
Bacillus cereus ATCC 11778 – 50µg/mL – Paulo et al., 2010
TISTR 687 – 64µg/mL – Promgool et al., 2014
Bacillus subtilis MTCC 2756 Isolated from Kalimpong, India 16.5µg/mL 32µg/mL Kumar et al., 2012b
Listeria monocytogenes LMG 16779 serovar 1/2a – 200µg/mL – Ferreira and Domingues, 2016
LMG 16780 serovar 1/2b – 200µg/mL – Ferreira and Domingues, 2016
LMG 13305 serovar 4b – 200µg/mL – Ferreira and Domingues, 2016
Listeria innocua LOP 9 Isolated from sheep milk 200µg/mL – Ferreira and Domingues, 2016
LMG 16779 – 200µg/mL > 400µg/mL Oliveira et al., 2017
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mechanism of action of resveratrol which include DNA damage
(Subramanian et al., 2016), cell division impairment (Haranahalli
et al., 2016), oxidative membrane damage (Subramanian et al.,
2014), and also metabolic enzymes inhibition (Dadi et al., 2009).
Many antibiotics induce oxidative stress in target bacteria
by producing ROS that cause oxidative damage to DNA,
subsequently leading to cell death (Goswami et al., 2006). Even
though the antioxidant properties of resveratrol are attributed to
it being a free radical scavenger and its ability to promote activity
of various antioxidant enzymes, depending on the concentration
of resveratrol and the target cell types, resveratrol can also
exhibit pro-oxidant properties (de la Lastra and Villegas, 2007).
In fact, recent studies indicated that resveratrol did not result
in generation of ROS in E. coli (Subramanian et al., 2014;
Haranahalli et al., 2016); the study instead suggested that the
inhibition of E. coli by resveratrol may be mediated through site-
specific oxidative membrane damage (Subramanian et al., 2014)
though the mechanism behind the membrane damage is still
under investigation.
Another proposed antibacterial mechanism of resveratrol may
be through the generation of Cu(II)-peroxide complex upon
reduction of Cu(II) to Cu(I) with resultant DNA cleavage and
cell death (Fukuhara and Miyata, 1998). Fukuhara and Miyata
(Fukuhara and Miyata, 1998) proposed that resveratrol binds
to Cu(II) to form a Cu(II)-peroxide complex, which leads to
reduction of Cu(II) to Cu(I). The Cu(II)-peroxide complex binds
DNA to form DNA-resveratrol-Cu(II) ternary complex and this
leads to DNA scission and breakage (Figure 3). The reduction of
Cu(II) to Cu(I) is necessary for DNA cleavage to occur. When
buthacuprione, a Cu(I) chelating agent, was added to solution
containing resveratrol and Cu(II), there was a reduction in the
levels of the nicked form of DNA produced from supercoiled
DNA, indicating reduction in DNA cleavage (Fukuhara and
Miyata, 1998). Additionally, the number and positions of the
hydroxyl group in the stilbene backbone also have an effect on
DNA cleavage activity. Resveratrol with a 4-hydroxy group has
pro-oxidant activity but isoresveratrol (Figure 4A), an analog of
resveratrol with a 3-hydroxy group did not reduce Cu(II) and
cause DNA cleavage. The 4-hydroxy group is responsible for
its high affinity binding to both Cu(II) and DNA in forming
a ternary complex to cleave DNA efficiently. Furthermore,
dihydroresveratrol (Figure 4B) was shown to have decreased
DNA cleaving ability compared to resveratrol, which indicates
the importance of the double bond in resveratrol which not only
provides planarity to the structure for effective DNA binding,
but also confers the stability of the 4-oxy radical form (Fukuhara
et al., 2006). A more recent study by Subramanian et al. (2016)
suggested that DNA damage induced by resveratrol in E. coli
could be a much later event occurring only after the membrane
integrity has been compromised, indicating that there is much
to be explored in order to fully understand the mechanism of
reservatrol’s action.
Another proposed mechanism of resveratrol’s antibacterial
activity is through the inhibition of the electron transport chain
(ETC) and F0F1-ATPase, thereby inhibiting the proliferation
of pathogenic microorganisms by reducing cellular energy
production (Madrigal-Perez and Ramos-Gomez, 2016). A study
by Dadi et al. (2009) found that resveratrol inhibited E. coli ATP
synthase activity, leaving only 60% residual activity. Resveratrol
(at 100µM) was also found to decrease complex III activity by
competing with coenzyme Q, leading to about 20% reduction in
enzyme activity (Zini et al., 1999). In another study, resveratrol
was found to inhibit enzymatic activity of F0F1-ATPase/ATP
synthase in rat brain and liver in a concentration-dependent
manner (Zheng and Ramirez, 2000). Similarly, a significant
reduction of metabolic activity was observed in the genus
Arcobacter bacteria upon treatment with resveratrol (Ferreira
et al., 2014).
Reservatrol also appears to have an inhibitory action on
cell division through its actionon filamentous temperature
sensitive protein (FtsZ), a GTP-dependent prokaryotic cell
division protein responsible for cell division through formation
of dynamic Z-ring in the middle of cell. Inhibiting expression
of FtsZ gene leads to a decrease in Z-ring formation in cells
and therefore inhibition of cell division (Haranahalli et al.,
2016). By using phase contrast microscopy, Hwang and Lim
(2015) observed that the length of resveratrol treated E. coli
cells increased in a dose-dependent manner, suggesting that the
elongation was due to interference of septum formation, which
therefore indicated a failure of cell division. To confirm the
effect of resveratrol on Z-ring formation, they used an E. coli
strain JW0093 containing plasmid that expressed one or more
Z-rings. Confocal microscopy showed that E. coli expressed Z-
ring formation in the absence of resveratrol while treatment
with resveratrol diminished the appearance of Z-rings. Western
blot analysis was used to further confirm the inhibition of FtsZ
expression by resveratrol, the analysis of which showed a decrease
in FtsZ levels in E. coli treated with resveratrol. These results
led to them conclude that the antibacterial activity of resveratrol
was attributed to suppression of FtsZ gene expression, thereby
inhibiting Z-ring formation and cell division (Hwang and Lim,
2015).
ANTIBIOFILM AND ANTIVIRULENCE
ACTIVITIES OF RESVERATROL AGAINST
FOODBORNE BACTERIA
One of bacteria’s survival strategies is the ability to form
biofilms where they adhere to various surfaces and form
sessile biofilm communities using a self-produced extracellular
polymeric matrix. These biofilms produced by pathogenic
foodborne bacteria can cause serious health risks due to their
inherent resistance to antimicrobial agents, host defenses and
external stresses, which make them difficult to eradicate and
can be an additional factor leading to antibiotic resistance
(Cho et al., 2013, 2015; Lee J. H. et al., 2014). In food
industries, the biofilms of spoilage or pathogenic bacteria
represent a considerable problem as they form on food surfaces
as well as the processing environment, leading to postprocessing
contamination and cross-contamination. As an intercellular
communication mechanism, quorum sensing regulates a variety
of physiological functions of bacteria including the virulence and
biofilm formation (Deep et al., 2011) which could limit bacterial
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FIGURE 3 | Schematic diagram of resveratrol pro-oxidant activity (de la Lastra and Villegas, 2007).
FIGURE 4 | Chemical structures of (A) isoresveratrol and (B) dihydroresveratrol.
proliferation in foods and food spoilage. Hence, new alternatives
to antibiotics that could eradicate bacterial biofilms and diminish
virulence of foodborne bacteria could be a promising strategy to
ensure food safety and quality (Cho et al., 2013).
Considering the complexity and heterogeneity of biofilm
structure, several parameters have to be taken into account
when selecting the proper measurement endpoint for antibiofilm
screens (Fallarero et al., 2014), which includes the measurement
of the biomass, biofilm viability as well as the extracellular
matrix of the biofilm. The literature documents several methods
that have been employed to assess the antibiofilm activity
of resveratrol; these methods include the quantification of
the biofilm using crystal-violet dye (Lee K. et al., 2014;
Qin et al., 2014), quantification of bacterial viability using
metabolic assays (MTT) (Duarte et al., 2015) and microscopic
evaluation using scanning electronmicroscope and confocal laser
scanning microscope (Lee J. H. et al., 2014; Cho et al., 2015).
Furthermore, studies also further investigated the antibiofilm
associated mechanisms of resveratrol by assessing the effect of
resveratrol on the genes associated to the regulation of biofilm
development (Qin et al., 2014). Several studies have reported
the biofilm inhibitory activity of resveratrol against both Gram
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positive and Gram-negative foodborne pathogens (Tables 3,
4). Differential activities of resveratrol in inhibiting biofilm
formation and eradicating biofilm already formed were observed
against specific species of foodborne pathogens. Previous work
demonstrated that resveratrol appears effective in inhibiting
biofilm formation by S. aureus (Moran et al., 2014; Qin et al.,
2014), L. monocytogenes (Ferreira and Domingues, 2016), E. coli
O157:H7 (Lee et al., 2013), Campylobacter sp. (Duarte et al.,
2015), and V. cholerae (Augustine et al., 2014).
Qin et al. (2014) demonstrated that resveratrol at 100µg/mL
caused 39.85% inhibition of methicillin-resistant S. aureus
(MRSA) biofilm formation and at 150µg/mL, caused 23.42%
removal of preformed biofilm. This was also visualized by SEM
where 100µg/mL and 150µg/mL resveratrol both resulted in
thinner biofilm post-treatment. In addition, the combination
of resveratrol 150µg/mL and vancomycin 8µg/mL resulted in
55.43% removal of preformed biofilm which suggested potential
of resveratrol as adjunct therapy in MRSA biofilm infection
for its synergistic activity (Qin et al., 2014). It was proposed
the antibiofilm activity of resveratrol might be due to its
ability to cause interference in quorum sensing thus affecting
synthesis of surface proteins and capsular polysaccharides—
downregulation of genes (cap5ABCFG) responsible for capsular
polysaccharide synthesis was reported with resveratrol treatment
at 100µg/mL. The combination of resveratrol and vancomycin
was also found to downregulate the virulence gene clfA and
biofilm gene spoVG. The authors proposed that the synergistic
activity of the resveratrol/vancomycin combination was due
to vancomycin induced upregulation of the genes associated
with purine metabolism (purADHN) which was observed in
the combination treatment but not in resveratrol alone (Qin
et al., 2014). As such, the combinatorial treatment was more
effective in removing preformed biofilm as it induced purine
metabolism and reduced capsular polysaccharide synthesis (Qin
et al., 2014). Furthermore, there was additional evidence showing
the inhibitory effect of resveratrol on biofilm formation by
enteropathogenic S. aureus in which resveratrol at sub-inhibitory
concentrations of 100µg/mL exerted 20 to 45% antibiofilm
activity (Moran et al., 2014).
However, there have been also been several previous studies
reporting negative inhibitory effect of resveratrol against biofilm
formation bymethicillin-sensitive S. aureus (MSSA) (Lee K. et al.,
2014; Cho et al., 2015). Lee K. et al. (2014) reported trans-
resveratrol at 100µg/mL had no significant effect in reducing
biofilm formation in S. aureus ATCC6538 when compared
to control. Similarly, Cho et al. (2015) also reported trans-
resveratrol had no antibiofilm activity on S. aureus ATCC6538
at concentrations up to 100µg/mL. This data seems to highlight
that the antibiofilm activity of resveratrol could be strain specific,
particularly toward MRSA and enteropathogenic S. aureus but
not S. aureus ATCC6538. The differential antibiofilm activity
of resveratrol toward the different strains of S. aureus could
be explained by the difference in the involvement of multiple
molecules and factors including the adhesion factors, quorum
sensing and capsular polymers possessed by the bacterial
strains to form biofilm (Karatan and Watnick, 2009; Moran
et al., 2014). Besides that, the divergent findings could also be
related to the varying methodologies employed by respective
studies in assessing the antibiofilm properties of resveratrol.
Particularly, the spectroscopic assay using the crystal violet
stain to quantify the total biofilm biomass is subject to
several limitations, including species dependence, requirement
for individual optimization of protocols (e.g., period for biofilm
formation, development, maturation, staining) and it is also
unable to discriminate between the different components in the
biofilm (e.g., living and non-living cells; Pantanella et al., 2013;
Bueno, 2014). To differentiate living or dead microorganisms
within the biofilm, the crystal violet method could be coupled
with bacterial viability assays such as conventional viable plate
counting and metabolic assays such as MTT (Fallarero et al.,
2014).
Contamination of food by L. monocytogenes is common
in food processing environments due to their hardy growth
characteristics and ability to attach to stainless steel and
many surfaces to form biofilm (Donnelly, 2001). Often, L.
monocytogenes is associated with foodborne disease outbreaks
characterized by widespread distribution and high mortality
rates. Thus, effective strategies to remove or inhibit biofilm
formation by L. monocytogenes would be of tremendous value to
the food processing industry. In 2016, Ferreira and Domingues
(2016) demonstrated that resveratrol at MIC of 200µg/mL
produced approximately 60 to 70% biofilm inhibition against
three L. monocytogenes strains (LMG 16779 serovar 1/2a, LMG
16780 serovar 1/2b, LMG 13305 serovar 4b) and Listeria innocua
LOP 9 isolated from sheep’s milk. They also reported that L.
monocytogenes serovar 1/2a, the most commonly found serovar
in food processing plants was the most sensitive strain toward
biofilm inhibition by resveratrol (Ferreira and Domingues,
2016). This study claimed to be the first to demonstrate the
inhibitory effect of resveratrol against biofilm formation by L.
monocytogenes (Ferreira and Domingues, 2016).
Trans-resveratrol was also shown to be an effective antibiofilm
and antiquorum sensing agent against enterohemorrhagic E. coli
O157:H7 (EHEC) (Lee et al., 2013). Using trans-resveratrol at
10µg/mL, biofilm formation as well as swimming and swarming
abilities of EHEC were inhibited through down-regulation of
several quorum sensing genes. They showed that resveratrol at
20µg/mL downregulated the expression of curli genes (csgA
and csgB), motility gene (flhD, fimA, fimH, and motB) and
autoinducer-2 (AI-2) quorum sensing gene (lsrA, luxS, and luxR)
(Lee et al., 2013). The study also demonstrated specific and
selective inhibitory effect of trans-resveratrol against EHEC but
did not harm the commensal E. coli strains, suggesting that
possible application of resveratrol as an antibiofilm compound in
combination with lower dose of antibiotics to maximize removal
of pathogen without rendering development of antibiotic
resistance while protecting commensal microflora (Lee et al.,
2013).
C. jejuni and C. coli are the leading agents responsible for
bacterial gastroenteritis in humans worldwide from consumption
of contaminated poultry meat and products. They also form
biofilms that are resistant to disinfectant and represent a
major issue within the food industry. Several studies have
been conducted to investigate the potential of resveratrol as an
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antibiofilm and antiquorum sensing agent againstCampylobacter
bacteria. Duarte et al. (2015) reported resveratrol at 200µg/mL
resulted in 63–93% biofilm inhibition in four tested bacteria
strains (C. coli 873, C. jejuni 225421, and A. butzleriAB36/11 and
INSA 776). With reference to preformed biofilm, 200 nµg/mL
resveratrol caused 80% reduction in biofilm formation for
both Campylobacter strains and A. butzleri AM36/11, and 64%
reduction for A. butzleri INSA 776. The reported concentration-
dependent antibiofilm activity of resveratrol in inhibiting biofilm
formation and in diminishing preformed biofilm in all four
bacteria strains even at sub-inhibitory concentration of 6.25–
50µg/mL suggests that there could be significant applications
for this compound. The authors proposed that the effect of
resveratrol on biofilm formation is related to interference in
the expression of biofilm-related genes as shown in study by
Lee et al. (2013), and the antibiofilm activity on preformed
biofilm was related to the effect on quorum sensing (Reeser
et al., 2007; Gölz et al., 2012). Klancnik et al. (2017) examined
the effect of resveratrol on the inhibition of biofilm formation
(measured as adhered biomass) by C. jejuni and the culturability
and viability of the adhered cells post treatment with resveratrol.
Sub-inhibitory concentration (12.5–200µg/mL) of resveratrol
resulted in 40% inhibition of C. jejuni biofilm formation and 20–
30% inhibition was achieved at other lower concentrations tested.
When tested at MIC, 2x MIC and 5x MIC (MIC = 313µg/mL),
resveratrol resulted in even higher percentage inhibition in
biomass formation, and reduced culturability and viability of the
adhered cells by 50–60%.
Resveratrol was also shown to exhibit antibiofilm activity
against Vibrio bacteria. Augustine et al. (2014) reported
concentration dependent inhibition of percentage biofilm
formation in Vibrio cholerae O1 MCVO9; at 15–30µg/mL,
resveratrol inhibited biofilm formation by 64–85%. Reduction
of cells adherent to the coverslip was visualized using confocal
laser microscopy whereby the thickness of the biofilm formed
was significantly different between resveratrol treated cells and
control. Meanwhile, Kim et al. (2015) reported no significant
reduction in percentage biofilm formation in Vibrio cholera
O1 El Tor serotype Inada strain N16961 after treated with
10µg/mL of resveratrol. Perhaps, a higher concentration of
resveratrol is needed to inhibit the biofilm formation by V.
cholera O1 El Tor serotype as shown by the earlier study
with positive inhibitory effect by resveratrol at 15–30µg/mL
against V. cholerae O1 MCVO9 (Augustine et al., 2014). Besides
the selective antibiofilm activity demonstrated by resveratrol
against V. cholerae, it was demonstrated that resveratrol
inhibited cholera toxin induced cAMP accumulation in Vero
cells through the suppression of cholera toxin internalization
(Morinaga et al., 2010). Collectively, the evidence suggests that
resveratrol has the potential to be developed into an anti-
Vibrio agent that provides protective effects against cholera
infection.
Although the existing evidence indicates that resveratrol
exhibits antibiofilm properties against various foodborne
pathogens, substantial efforts using reliable quantification
methods are still needed in order to show that resveratrol
is truly an effective antibiofilm agent. Clearly, the current
evidence warrants further work to elucidate the exact mechanism
of action of resveratrol in the disruption or inhibition of
foodborne pathogen biofilms. Also, these antibiofilm properties
of resveratrol hold promise for the development of a molecule
that may be used either on its own or as an adjuvant to
existing suppression or eradication strategies against foodborne
pathogens.
APPLICATION AND EFFICACY OF
RESVERATROL IN THE FOOD SYSTEM
While the laboratory results are very encouraging, it should
be borne in mind that there are potential limitations to the
degree to which the study findings may be applied in real
world situations. Food and food products are rich in complex
nutrients, which may support growth of bacteria even better
than nutrient media, and it is likely a higher concentration of
antimicrobial might be needed to achieve the desired results
even though substantial antimicrobial activity is achieved in in-
vitro studies (Shelef, 1984; Gill et al., 2002). Intrinsic properties
such as fat, protein, water content, antioxidant, pH, food additive
and extrinsic properties such as storage condition, temperature,
and microorganism characteristics can also potentially diminish
the efficacy of the antibacterial agent (Tassou et al., 1995).
Furthermore, the possibility of nutritional and organoleptic
losses should also be noted when using an antibacterial agent to
improve microbial quality and safety of food. For example, in the
case of essential oils, despite their greater antimicrobial potential
(Burt, 2004; Lai et al., 2017) than resveratrol, their application
in food preservation is still limited by their intense aroma and
toxicity issues.
For resveratrol, even though promising results were obtained
from the in vitro experiments including the agar and broth
systems, applied studies are also mandatory to confirm its
effectiveness in food protection against foodborne pathogens.
Surendran Nair et al. (2016) examined the enhancement of
thermal inactivation of E. coliO157:H7 inoculated on beef patties
in the presence of resveratrol. They reported no decline in E.
coli count irrespective of treatment throughout the refrigerated
storage (4◦C for 5 days) in uncooked patties. In patties that are
stored at 4◦C for 5 days and cooked to an internal temperature
of 65◦C, significant reduction (>3 log CFU/g) of E. coli was
observed for day 1, 3, and 5 at 0.2% w/w resveratrol in
comparison to control whereas at 0.1%w/w, significant reduction
was observed at day 3 and 5. A synergistic effect was observed
when either concentration of resveratrol was combined with
chitosan (1% w/w), which significantly reduced count, while
chitosan + resveratrol 0.2% w/w completely diminished E. coli
count in day 3 and 5 (Surendran Nair et al., 2016). They
proposed the synergistic effect observed was because chitosan,
being an emulsifier, can solubilise resveratrol, thereby improving
the distribution of resveratrol in meat (Klinkesorn, 2013).
Enhancement of thermal activation in the presence of resveratrol
suggested that heat caused damage to cell membrane integrity,
thereby allowing better penetration of resveratrol into cells.
Similarly, resveratrol was shown to cause oxidative damage to
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cell membrane, which may help to enhance the killing when
compared to heat alone (Subramanian et al., 2014).
Ferreira and Domingues (2016) demonstrated the
antibacterial effect of resveratrol (200–400µg/mL) against
L. monocytogenes and L. innocua in four food models: UHT
treated skim milk, UHT treated whole milk, chicken juice and
lettuce leaf. They reported resveratrol significantly reduced
bacterial count for both strains in chicken juice and lettuce leaf
model. The effect was less pronounced for L. monocytogenes in
UHT-treated skim and whole milk, with no significant reduction
of bacteria in the whole milk. They proposed the observed
difference was due to higher fat content in whole milk which
protected the bacteria from inhibition by resveratrol. Due to
the hydrophobic nature of resveratrol, it might preferentially
dissolve in the lipid phase of milk, thus decreasing the amount
of active substance available to act on bacteria (Mejlholm and
Dalgaard, 2002).
Consumption of raw vegetables also represents a common
source of food borne infections, thus it is critical to control the
microbial load in the fresh produce particularly from the salad
supply chain, ensuring food safety and hygiene quality. Lai et al.
(2017) demonstrated the potential of resveratrol to be used as
a natural preservative to control the total viable microbial load
in alfalfa sprout and mushroom slices. They reported 0.9 log
reduction and 3.06 log reduction in microbial load in alfalfa
sprout and mushroom respectively after 24 h storage at 4◦C (Lai
et al., 2017).
There are some concerns with reference to resveratrol’s
impact on the organoleptic properties of the food, as it may
impart an astringent flavor and bitterness to the food. Gaudette
and Pickering (2011) reported an increase in the perception of
bitterness with increasing concentrations of resveratrol added to
wine. To minimize the effect of resveratrol on the organoleptic
properties of the food, techniques such as encapsulation of
resveratrol by spray-drying was suggested by Koga et al.
(2015) to reduce the perception of bitterness. They reported
a higher taste detection threshold for resveratrol (313µg/mL)
encapsulated with sodium caseinate than unencapsulated
resveratrol (90µg/mL) in protein solution (Koga et al., 2015).
To date, studies on the sensory evaluation of resveratrol in the
food system are still limited, thus further work is needed to
improve the utilization of resveratrol as a food preservatives by
minimizing its taste altering effect.
BIOAVAILABILITY, SAFETY PROFILE, AND
DRUG-DRUG INTERACTIONS OF
RESVERATROL
Resveratrol was reported to be extensively absorbed and
metabolized but with very low bioavailability. Walle et al.
(2004) reported that 70% of an oral dose of 25mg resveratrol
was absorbed but the concentration remaining unchanged in
plasma was <5 ng/ml. They proposed that this was because
resveratrol was metabolized in liver and intestine by sulfate and
glucuronic acid conjugation and by hydrogenation of aliphatic
double bond. In addition to that, inter-individual variability of
resveratrol metabolism was also reported by Bode et al. (2013),
where they proposed the difference seen might be attributed to
variation in human gut microflora in microbial transformation
of resveratrol. Thus, to effectively utilize resveratrol in foods and
pharmaceuticals, many efforts have been reported to improve
the bioavailability of resveratrol through various encapsulation
methods.
The safety profile of resveratrol has been well documented and
is safe for consumption up to 5 g per day in healthy humans.
Several studies reported that gastrointestinal side effects such
as diarrhea, nausea, and abdominal pain were common when
administered at high doses (Brown et al., 2010; Chow et al., 2010;
Howells et al., 2011; Anton et al., 2014; Sergides et al., 2016).
Brown et al. (2010) reported mild gastrointestinal symptoms
when resveratrol was administered at a doses of 2.5 g/day while
Sergides et al. (2016) reported resveratrol administered 500
mg/day was well tolerated in human. Similarly, Howells et al.
(2011) reported mild gastrointestinal symptoms as the primary
side effect experienced by patients taking resveratrol 5 g/day, with
other less common side effects such as chills, rash, skin irritation
and vascular flushing also reported. Anton et al. (2014) reported
short-term resveratrol administration (90 days) at 300 mg/day
and 1 g/day was well tolerated in overweight elderly and did not
significantly altered blood chemistries. Chow et al. (2010) also
reported high tolerability of resveratrol administered at 1 g/day
as most side effects were mild and transient.
The potential drug-resveratrol interaction is also an important
aspect requiring considerable attention. Co-administration of
resveratrol together with other drugs may potentially result in
drug-resveratrol interactions by changing the pharmacokinetics
of the drug or resveratrol. Resveratrol inhibits several key CYP
enzymes such as CYP3A4, 1A2, 2C9, 2D6, and 2E1. Thus, high
intake of resveratrol may theoretically reduce the metabolism
of drugs by CYP enzymes and increase their bioavailability
and potential toxicity. In a clinical trial study by Chow et al.
(2010), they reported 1.33-fold increase in AUC for buspirone
following co-administration of resveratrol at 1 g/day for 4
weeks due to inhibition of CYP3A4. Similarly, Choi et al.
(2009) reported 2.2 and 2.3-fold increase in Cmax and AUC of
nicardipine respectively in male rats following co-administration
of resveratrol at 10 mg/kg body weight. Potential systemic drug-
resveratrol interaction should be considered at high doses at
> 1 g/day. However, the risk of interaction is minimal at low
milligram doses as resveratrol has a very low bioavailability
and is rapidly metabolized by conjugation in vivo. Therefore,
the systemic concentration of free resveratrol is far below the
conjugates. In addition, there have been no reports so far of
inhibition of CYPs by resveratrol conjugates, and high plasma
protein binding of resveratrol also reduces the risk of potential
interactions (Detampel et al., 2012).
COMMERCIALIZATION AND FUTURE
DIRECTIONS
At the time of writing, more than 5000 patents were
found from searching “Scopus” using search terms
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“resveratrol” AND “antibacterial” OR “antimicrobial” limit
to title/abstract/keywords. Some of the patented products
containing resveratrol included antibacterial foot spray and
hand cleanser (Yoo and Kim, 2013; Zhu et al., 2016), botanical
fungicide (Li et al., 2015), skin care products (He et al., 2017;
Lei et al., 2017), food supplements (Sardi and Solomonson,
2005; Pall, 2014; Arroyo Paz, 2017) and antioxidant eye drops
(Kador, 2016). Clearly, in the future, more research is required
to unravel the potential of resveratrol to be developed into
biopharmaceutical products. As the studies currently focus only
on in-vitro determination of biological activity of resveratrol,
there is an urgent need for studies on the efficacy of resveratrol
in in vivo animal models associated with foodborne infections.
In addition, to obtain the full potential of resveratrol, further
evaluation of the mechanism of action of resveratrol will be
needed to strengthen its practical applications and significance
in future research. Further investigations could be extended to
interactions between resveratrol and the food ingredients or food
additives as well as its effect on the organoleptic properties of
the product. Studies of the stability of resveratrol under various
storage conditions and processing conditions are also needed to
confirm its applicability in the food industry.
CONCLUSION
Food contamination by pathogenic foodborne bacteria is a major
health risk to the public and the situation is being further
exacerbated by the emergence of antibiotic resistant strains
which are promoted by the ever-increasing usage of antibiotics.
Natural antimicrobials seem to hold promise as an alternative to
antibiotics and can be used to decrease the spread of resistant
strains. Resveratrol exhibits promising antibacterial activities
against important foodborne bacteria including S. aureus, L.
monocytogenes, C. jejuni, E. coli, and V. cholerae, possibly
mediated through DNA cleavage, membrane damage, reduced
cellular metabolic activity and inhibition of cell division. The
antibiofilm and antivirulence activities of resveratrol can be
exploited as stand-alone alternative therapy or as coadjuvants
to current antibiotic therapy against foodborne pathogens.
Furthermore, resveratrol also proved to be effective in inhibiting
several foodborne pathogens in different types of food matrix,
which supports its potential use as an alternative food additive
or preservative to ensure high quality food products which are
safe to be consumed. Based on the current toxicological data,
resveratrol was shown have low toxicity even when taken at high
doses with mild gastrointestinal disturbances being the major
side effect reported. Overall, this review highlights the potential
application of resveratrol as an antimicrobial biopharmaceutical
product as well as to have significant applications in the food
industry as a food preservative.
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